Welcome to our dedicated page for Lifemd news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
News for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) is closely tied to developments at LifeMD, Inc., the issuer of this preferred security. LifeMD regularly publishes updates about its virtual primary care and pharmacy operations, financing activities, and corporate governance, all of which can be relevant to investors following LFMDP.
Company announcements describe LifeMD as a provider of virtual primary care services and pharmacy solutions, with telemedicine, laboratory access, and pharmacy services supporting treatment across more than 200 conditions. News items highlight growth in telehealth revenue, expansion into areas such as weight management, women’s health, mental and behavioral health, and cardiometabolic care initiatives, and the evolution of its virtual care platform.
Investors tracking LFMDP can expect news related to LifeMD’s clinical programs, including collaborations with pharmaceutical manufacturers. Recent releases discuss expanded collaboration with Novo Nordisk, access to Wegovy and Ozempic within LifeMD’s weight management program, and the addition of the Wegovy pill to its virtual obesity care offering. Other updates cover developments in women’s health programs, including the appointment of clinical advisors, and the scaling of men’s health and RexMD-branded services.
Corporate and financial news is also significant for LFMDP followers. LifeMD has issued press releases on quarterly financial results, changes in independent registered public accounting firms, the divestiture of its majority interest in WorkSimpli Software LLC to focus on virtual care and pharmacy, and the establishment of a revolving credit facility. The company has additionally announced quarterly cash dividends on the 8.875% Series A Cumulative Perpetual Preferred Stock.
By reviewing the LFMDP news feed, readers can monitor how LifeMD’s virtual care strategy, partnerships, financial decisions, and governance updates may influence the context in which this preferred stock operates. Regular news provides a consolidated view of operational milestones and capital structure developments that matter to preferred and common equity holders alike.
LifeMD (Nasdaq: LFMD) launched Novo Nordisk's industry-first Wegovy® (semaglutide) telehealth subscription program on March 31, 2026, expanding its commercial collaboration with Novo Nordisk. Eligible patients can receive structured pricing with up to $1,200 annual savings for injectable Wegovy and $600 for oral therapy.
The program offers end-to-end virtual care across all 50 states, ongoing clinical oversight, nationwide diagnostic testing, and simplified billing, and is available at LifeMD's weight management site.
LifeMD (Nasdaq: LFMD) declared a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) of $0.5546875 per share.
The dividend is payable April 15, 2026, to holders of record at the close of business on April 3, 2026.
LifeMD (Nasdaq: LFMD) appointed Atul Kavthekar as Chief Financial Officer, effective March 16, 2026, and announced additional leadership changes to support growth. Marc Benathen will remain through March 31, 2026, to assist transition. LifeMD disclosed an employment inducement of 675,000 restricted stock units for Mr. Kavthekar, split between service- and performance-based vesting.
LifeMD also named Chris Pisano Chief Marketing Officer and promoted Jessica Friedeman to Chief Business Officer; Friedeman joined LifeMD in January 2023.
LifeMD (Nasdaq: LFMD) reported full year 2025 revenue of $194.1 million (up 25%) and adjusted EBITDA of $15.3 million (up 309%). Q4 revenue was $46.9 million (+4%) with adjusted EBITDA of $4.8 million (+348%).
The company exited 2025 with $36.8 million cash, no debt, ~323,000 active subscribers, a benefits infrastructure to cover ~220 million Americans by Q2, and a post‑year‑end launch of oral Wegovy with >80% initiation among new weight management patients.
LifeMD (Nasdaq: LFMD) announced management will participate in two virtual investor conferences in March 2026.
Management will attend the Mizuho Securities Healthcare Technology Conference on March 5 with virtual one-on-one meetings, and the KeyBanc Capital Markets Healthcare Forum March 17-18 with a fireside chat and a panel on March 18.
LifeMD (Nasdaq: LFMD) will report fourth quarter and full-year 2025 financial results after market close on March 9, 2026 and will host a conference call and webcast at 4:30 p.m. Eastern the same day.
Dial-in numbers, conference ID LIFEMD, and a live/archived webcast link will be available for investors.
LifeMD (Nasdaq: LFMD) closed a new senior secured revolving credit facility with Citizens Bank providing up to $50 million of total availability, consisting of $30 million committed availability plus an accordion option of up to $20 million. The facility matures on January 2, 2029. As of closing, no amount was drawn and the company stated it expects existing cash and cash flow to fund organic growth. Interest is priced on a leverage-linked grid at either Term SOFR +150–225 bps or Alternate Base Rate +50–125 bps, with unused-commitment fees of 0.225%–0.30% and no upfront fee.
LifeMD (NASDAQ: LFMD) expanded its collaboration with Novo Nordisk to offer Wegovy pill (oral semaglutide) through LifeMD’s telehealth and integrated NovoCare Pharmacy services. The U.S. FDA approved the Wegovy pill on Dec 22, 2025 as the first oral GLP-1 for chronic weight management and certain cardiovascular risk reduction. A 64-week Phase 3 trial showed 16.6% mean weight loss versus 2.7% for placebo. Eligible patients can access Wegovy pills via LifeMD starting at $149/month, with staged price increases effective Apr 15, 2026. LifeMD offers virtual visits, nationwide testing, clinical oversight, and home delivery across all 50 states.
LifeMD (Nasdaq: LFMD) announced a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) of $0.5546875 per share. The dividend is payable on January 15, 2026 to holders of record at the close of business on January 5, 2026. This declaration establishes the payment amount and the key record and payment dates for preferred shareholders.
LifeMD (Nasdaq: LFMD) announced on November 24, 2025 that it was recognized on the 2025 Deloitte Technology Fast 500 and on the inaugural TIME’s America’s Growth Leaders of 2026 list.
LifeMD said the honors reflect its continued revenue growth, financial stability, and expanding position in health technology driven by virtual primary care, pharmacy solutions, and growth in weight management, mental health, and hormone replacement therapy. Management highlighted investments in a differentiated enterprise platform, an affiliated compounding pharmacy, expanded insurance coverage, and strategic employer, pharma, and commercial partnerships.